Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia

Summary

The goal of this clinical research study is to find the highest tolerable dose of PLM-102 that can be given to patients who have AML/MDS that is refractory and/or relapsed. The safety of PLM-102 will also be studied.

Timeline

Start

2026-10-01

Primary completion

2029-06-01

Completion

2031-06-01

Drugs

Indications